Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD ... as well as PT009 – a combination of budesonide formoterol ...

umeclidinium and vilanterol by the end of the year in COPD. The combination is an inhaled corticosteroid, long acting muscarinic antagonist and a long-acting beta agonist. It met its co-primary ...

DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...

Eligible patients had COPD, were ages 40 or older ... study inhaler or an inhaled corticosteroid-LAMA-LABA combination via separate inhalers. The cohort included 87,751 individuals, from which ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

A further 500 were given the triple combination but in two inhalers. COPD is term used to describe a number of progressive lung diseases such as emphysema. The main cause is smoking, although the ...

Inhaled corticosteroids (ICS), short ... AstraZeneca), which are ICS–LABA combinations, are other popular COPD drugs. A major limitation with the current corticosteroid therapy is that they ...

AstraZeneca recently announced the completion of clinical studies for a next-generation propellant (NGP) version of its chronic obstructive pulmonary disease (COPD) inhaler, Breztri. This new ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...